[go: up one dir, main page]

WO2004093995A3 - Utilisation d'antioxydants pour traiter les troubles associes a la perte osseuse - Google Patents

Utilisation d'antioxydants pour traiter les troubles associes a la perte osseuse Download PDF

Info

Publication number
WO2004093995A3
WO2004093995A3 PCT/GB2004/001695 GB2004001695W WO2004093995A3 WO 2004093995 A3 WO2004093995 A3 WO 2004093995A3 GB 2004001695 W GB2004001695 W GB 2004001695W WO 2004093995 A3 WO2004093995 A3 WO 2004093995A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone loss
antioxidants
loss disorders
treat bone
antioxidant
Prior art date
Application number
PCT/GB2004/001695
Other languages
English (en)
Other versions
WO2004093995A2 (fr
Inventor
Timothy John Chambers
Karen Fuller
Christopher John Jagger
Jenny Maree Lean
Original Assignee
St Georges Entpr Ltd
Timothy John Chambers
Karen Fuller
Christopher John Jagger
Jenny Maree Lean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Entpr Ltd, Timothy John Chambers, Karen Fuller, Christopher John Jagger, Jenny Maree Lean filed Critical St Georges Entpr Ltd
Publication of WO2004093995A2 publication Critical patent/WO2004093995A2/fr
Publication of WO2004093995A3 publication Critical patent/WO2004093995A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon l'invention, il est possible de traiter ou de prévenir les troubles associés à la perte osseuse par administration d'un agent qui accroît les taux de défenses contre les oxydants et/ou d'au moins un antioxydant chez un sujet. Ledit agent peut être un antioxydant. Cet agent peut agir directement pour accroître les taux d'antioxydant et/ou les défenses contre les oxydants. En variante, ledit agent peut agir indirectement.
PCT/GB2004/001695 2003-04-17 2004-04-19 Utilisation d'antioxydants pour traiter les troubles associes a la perte osseuse WO2004093995A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308952.1 2003-04-17
GBGB0308952.1A GB0308952D0 (en) 2003-04-17 2003-04-17 Method

Publications (2)

Publication Number Publication Date
WO2004093995A2 WO2004093995A2 (fr) 2004-11-04
WO2004093995A3 true WO2004093995A3 (fr) 2005-04-21

Family

ID=9956987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001695 WO2004093995A2 (fr) 2003-04-17 2004-04-19 Utilisation d'antioxydants pour traiter les troubles associes a la perte osseuse

Country Status (2)

Country Link
GB (1) GB0308952D0 (fr)
WO (1) WO2004093995A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
WO2006024096A1 (fr) * 2004-08-31 2006-03-09 Chemgenex Pharmaceuticals Limited Procédé servant à moduler l'ostéoclastogénèse
US7956031B2 (en) 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
WO2007080630A1 (fr) * 2006-01-10 2007-07-19 Masayoshi Yamaguchi AGENT PERMETTANT D'AUGMENTER LE CONTENU MINÉRAL OSSEUX CONTENANT DE L'ACIDE p-HYDROXYCINNAMIQUE EN TANT QUE PRINCIPE ACTIF
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20100015085A1 (en) * 2006-05-01 2010-01-21 Johns Hopkins University Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress
US8101198B2 (en) * 2006-07-26 2012-01-24 The Regents Of The University Of California Osteogenic enhancer composition
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
WO2008128342A1 (fr) * 2007-04-18 2008-10-30 Mcgill University Composition favorisant la formation osseuse
ITMI20080172A1 (it) * 2008-02-05 2009-08-06 Bios Line Spa Formulazioni orali per la protezione delle vie respiratorie con particolare riferimento ai fenomeni infiammatori e neoplastici
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
DK2367549T3 (da) * 2008-12-30 2013-11-04 Hills Pet Nutrition Inc Anvendelse af alfalipoinsyre til behandling eller forebyggelse af nedbrydende ledsygdomme, osteoarthritis, bruskskade, og relaterede lidelser hos kæledyr
KR101169850B1 (ko) * 2008-12-30 2012-07-30 서울대학교산학협력단 트로락스를 포함하는 골 대사성 질환 또는 골 전이성 암 질환 예방 및 치료용 약제학적 조성물
US20140343104A1 (en) * 2011-08-26 2014-11-20 National University Corporation Nagoya University Osteogenesis promoter and use thereof
WO2016187394A1 (fr) 2015-05-19 2016-11-24 Van Wijnen Andre J Procédés et matériaux pour favoriser la formation osseuse
WO2017120420A1 (fr) * 2016-01-06 2017-07-13 The Trustees Of Columbia University In The City Of New York Utilisation de gaïacol pour la prévention et le traitement de glycogénoses
EP3593638A1 (fr) * 2018-07-09 2020-01-15 Université de Lausanne Fongicides pour prévenir et lutter contre des agents pathogènes fongiques
CN112089719A (zh) * 2020-09-07 2020-12-18 广州中医药大学第一附属医院 曲克芦丁在制备成骨相关药物中的应用
CN112972475A (zh) * 2021-03-24 2021-06-18 南京医科大学友谊整形外科医院有限责任公司 奥替普拉在制备防治骨质疏松产品中的应用
CN117883439A (zh) * 2024-01-18 2024-04-16 中国人民解放军陆军军医大学第一附属医院 吲哚-3-丙酸在制备抑制破骨细胞分化药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
JPH0687750A (ja) * 1992-09-08 1994-03-29 Taiyo Yakuhin Kogyo Kk 医薬組成物
JPH0840888A (ja) * 1994-07-28 1996-02-13 Ajinomoto Co Inc ミエローマ系腫瘍抗癌剤
JPH0881380A (ja) * 1994-09-09 1996-03-26 Suntory Ltd 高分子量ポリフェノールを有効成分として含有する抗歯周病剤並びに抗歯周病性食品
JPH11130644A (ja) * 1997-10-29 1999-05-18 Lion Corp 口腔用組成物
CA2012208C (fr) * 1989-03-27 2001-05-22 Julius Ozick Methode de traitement de la periodontite
US20020048798A1 (en) * 2000-03-15 2002-04-25 Avery Mitchell Allen Novel antioxidants
EP1214893A1 (fr) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Compositions pour améliorer la santé
EP1431385A1 (fr) * 2002-12-18 2004-06-23 Döhler GmbH Boisson contenant du xanthohumol

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
CA2012208C (fr) * 1989-03-27 2001-05-22 Julius Ozick Methode de traitement de la periodontite
JPH0687750A (ja) * 1992-09-08 1994-03-29 Taiyo Yakuhin Kogyo Kk 医薬組成物
JPH0840888A (ja) * 1994-07-28 1996-02-13 Ajinomoto Co Inc ミエローマ系腫瘍抗癌剤
JPH0881380A (ja) * 1994-09-09 1996-03-26 Suntory Ltd 高分子量ポリフェノールを有効成分として含有する抗歯周病剤並びに抗歯周病性食品
JPH11130644A (ja) * 1997-10-29 1999-05-18 Lion Corp 口腔用組成物
US20020048798A1 (en) * 2000-03-15 2002-04-25 Avery Mitchell Allen Novel antioxidants
EP1214893A1 (fr) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Compositions pour améliorer la santé
EP1431385A1 (fr) * 2002-12-18 2004-06-23 Döhler GmbH Boisson contenant du xanthohumol

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1994, HANIOKA T ET AL: "Effect of topical application of Coenzyme Q10 on adult periodontitis", XP002291089, Database accession no. EMB-1995041314 *
HALL T J ET AL: "THE ROLE OF REACTIVE OXYGEN INTERMEDIATES IN OSTEOCLASTIC BONE RESORPTION", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 207, no. 1, 6 February 1995 (1995-02-06), pages 280 - 287, XP002068360, ISSN: 0006-291X *
MOLECULAR ASPECTS OF MEDICINE 1994 UNITED KINGDOM, vol. 15, no. SUPPL., 1994, pages S241 - S248, ISSN: 0098-2997 *
NAKAMUTA HIROMICHI ET AL: "A novel bone-protective effect of taurine on low Ca diet-induced osteoporosis in rats", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 88, no. Supplement 1, 2002, & 75TH ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY; KUMAMOTO, JAPAN; MARCH 13-15, 2002, pages 108P, XP009034443, ISSN: 0021-5198 *
PATENT ABSTRACTS OF JAPAN vol. 0183, no. 47 (C - 1219) 30 June 1994 (1994-06-30) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 06 28 June 1996 (1996-06-28) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 07 31 July 1996 (1996-07-31) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 10 31 August 1999 (1999-08-31) *

Also Published As

Publication number Publication date
GB0308952D0 (en) 2003-05-28
WO2004093995A2 (fr) 2004-11-04

Similar Documents

Publication Publication Date Title
WO2004093995A3 (fr) Utilisation d'antioxydants pour traiter les troubles associes a la perte osseuse
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2006121518A3 (fr) Dispositifs electriques, agents prevenant la formation de cicatrices et compositions therapeutiques
WO2004093814A3 (fr) Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
WO2005079143A3 (fr) Formulations topiques pour le traitement d'etats dermatologiques
GB2434983A (en) Methods and compositions for wound healing
GB2442201A (en) Method of providing lubricious surfaces
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
WO2005065667A3 (fr) Compositions pour traiter ou prevenir l'obesite et les troubles de resistance a l'insuline
PT1682126E (pt) Benzazois substituídos e sua utilização como inibidores da quinase raf
WO2005063232A8 (fr) Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
WO2004019866A3 (fr) Compositions et procedes de traitement de maladies cardio-vasculaires
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
WO2004103283A3 (fr) Compositions comprenant un inhibiteur selectif de cyclooxygenase-2 et un stimulant de systeme nerveux central pour le traitement d'une lesion du systeme nerveux central
WO2004064719A3 (fr) Compositions synergiques et procedes pour potentialiser une activite antioxydante
WO2005044200A3 (fr) Procedes et compositions pour traiter des pathologies associees a la mcp-1
TW200500077A (en) Antioxidant-containing wipes and absorbent products for improving skin health
WO2005013911A3 (fr) Usages protecteurs et therapeutiques de tocotrienols
WO2004093813A3 (fr) Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
WO2006116374A3 (fr) Traitements de surfaces destines a favoriser la fixation tissulaire selective sur des implants medicaux
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
HK1046367A1 (zh) 治疗过敏和炎症症状
WO2004087045A3 (fr) Dispositifs, methodes et compositions permettant de prevenir la restenose
WO2004105689A3 (fr) Composition s'appliquant localement afin de traiter des lesions epidermiques et ses methodes d'utilisation
WO2004016151A3 (fr) Modulateurs de la prolifération des cellules du muscle lisse dérivés de pthrp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase